BeOne Medicines AG
BeOne Medicines's GHG Emissions Data Preview
In 2023, BeOne Medicines completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
BeOne Medicines has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into BeOne Medicines's Operational Emissions
In 2023, the total operational greenhouse gas (GHG) emissions of BeOne Medicines amounted to 78,948 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of BeOne Medicines increased by 37.87%, suggesting that the company faced challenges in reducing its emissions from its core operations.
BeOne Medicines's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are BeOne Medicines's Scope 1 emissions?
In 2023, the total Scope 1 emissions of BeOne Medicines were 2,463 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has BeOne Medicines reduced its Scope 1 emissions over time?
Since 2018, BeOne Medicines's Scope 1 emissions have increased by 360.37%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), BeOne Medicines's Scope 1 emissions decreased by 27.37%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are BeOne Medicines's Scope 2 emissions?
In 2023, BeOne Medicines reported Scope 2 greenhouse gas (GHG) emissions of 76,465 tCOâ‚‚e using the market-based method, and 76,485 tCOâ‚‚e using the location-based method.
Has BeOne Medicines reduced its Scope 2 emissions over time?
Compared to the previous year (2022), BeOne Medicines's Scope 2 emissions (Location-Based) rose by 41.98% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
What methodology does BeOne Medicines use for Scope 2 reporting?
In 2023, BeOne Medicines reported its Scope 2 emissions using the market-based method and using the location-based method.
BeOne Medicines's Scope 2 Emissions Over Time
- Total Scope 2 Location-Based
- Total Scope 2 Market-Based
- Total Scope 2 (Unspecified Calculation Method)
Insights into BeOne Medicines's Value Chain Emissions
In 2023, BeOne Medicines reported 476,965 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of BeOne Medicines includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
BeOne Medicines's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are BeOne Medicines's Scope 3 emissions?
In 2023, BeOne Medicines reported total Scope 3 emissions of 476,965 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 99.97% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.03% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2022), BeOne Medicines's Scope 3 emissions increased by 119.64%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does BeOne Medicines disclose?
In 2023, BeOne Medicines reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of BeOne Medicines's Scope 3 emissions?
In 2023, the largest contributors to BeOne Medicines's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 333,844 tCOâ‚‚e (69.99%)
- Capital Goods (Cat. 2): 97,211 tCOâ‚‚e (20.38%)
- Fuel- and Energy-Related Services (Cat. 3): 21,678 tCOâ‚‚e (4.54%)
BeOne Medicines's Scope 3 Emissions by Categories
Insights into BeOne Medicines's Total Carbon Footprint
In 2023, BeOne Medicines reported a total carbon footprint of 555,913 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 102.58% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to BeOne Medicines's total carbon footprint was Scope 3 emissions, accounting for 85.8% of the company's total carbon footprint, followed by Scope 2 emissions at 13.76%.